The phrase "sexually transmitted diarrhea disease" that spread across social media refers to shigellosis, an intestinal infection caused by Shigella bacteria. It is not a new disease and not a new outbreak; the term is a viral reframing of an older public-health issue that is genuinely becoming harder to treat. Shigella spreads through fecal–oral contact, which includes oral and anal sex, as well as through contaminated food or water. The trend drew attention because people re-shared existing reports and studies rather than because case numbers suddenly jumped.
The hashtag gained momentum in early October 2026 after older CDC data and summer research were recirculated online. USA Today published explainers on 9–10 October 2026, and ScienceAlert covered the same material. The coverage framed the issue as a sexually transmitted diarrhea disease, which is where the memorable and alarming phrasing came from. Public health agencies did not report a matching surge in real infections at that time.
According to the CDC, the United States recorded 13,921 shigellosis cases as of 26 September 2026, a figure reported by USA Today on 9 October 2026. That compares with 14,277 cases for the whole of 2025, so the totals are broadly similar rather than dramatically higher. The gap between a viral trend and stable case counts is the central point: attention rose faster than infections did. What is changing is not how many people get sick, but how treatable those infections are.
Shigella is a genus of bacteria that infect the gut and cause diarrhea, fever and stomach cramps. It spreads when tiny amounts of fecal matter reach the mouth, a route known as fecal–oral transmission. In sexual contexts, this happens mainly through oral–anal contact, which is why the infection appears disproportionately in sexual networks. Most healthy adults recover without treatment, but the illness can be severe in young children and people with weakened immune systems.
A CDC report published in the Morbidity and Mortality Weekly Report on 9 April 2026 analysed roughly 16,800 Shigella isolates collected between 2011 and 2023. Extensively drug-resistant strains, meaning strains resistant to most recommended antibiotics, rose from zero percent in 2011–2015 to 8.5 percent in 2023. Among patients with these extensively drug-resistant infections, 86 percent were men with a median age of 41, and about one third were hospitalized. No FDA-approved oral treatment currently exists for extensively drug-resistant Shigella.
In the same CDC dataset, 82 percent of patients with extensively drug-resistant infections had no recent international travel. That detail matters because it suggests the resistant strains are circulating domestically rather than being imported. Of those tested, 46.6 percent were living with HIV, which may reflect overlapping sexual networks and repeated antibiotic exposure rather than a direct causal link. These figures describe a specific sample of isolates and should not be read as a general population risk profile.
The trend is ultimately about antimicrobial resistance, not about a sudden epidemic. Each course of antibiotics creates pressure that favours bacteria able to survive treatment, and Shigella acquires resistance genes readily. Cambridge researchers reported in July 2026 that sexually transmitted Shigella strains spread and evolve resistance faster than strains transmitted by other routes. Estimates from that work suggest around 70 percent of sexually transmitted strains resist at least one relevant antibiotic.
The UK Health Security Agency reported 2,560 sexually acquired Shigella diagnoses in England in 2025, up from 2,318 in 2024 and 2,052 in 2023. That total exceeds pre-pandemic levels, and 54 percent of cases were recorded in London. More than half of the S. sonnei isolates tested were extensively drug-resistant, meaning they did not respond to ciprofloxacin, azithromycin and ceftriaxone together. The UKHSA figures cover England only and run to 2025.
UKHSA data for 2025 show that 86 percent of S. sonnei and 94 percent of S. flexneri isolates were multidrug-resistant or extensively drug-resistant. Resistance was high to ciprofloxacin at 83 percent, azithromycin at 58 percent and ceftriaxone at 73 percent. A separate outbreak identified between June 2025 and March 2026 involved 83 cases, 91.6 percent of them adult males, and carried the blaCTX-M-3 resistance gene. That gene had not previously been seen in UK sexual transmission, which makes the finding notable.
Shigellosis has several species, and the two most relevant here are S. sonnei and S. flexneri. S. sonnei is the species most often linked to sexual transmission in high-income countries, and it is also where much of the resistance is concentrated. S. flexneri, while less common in these outbreaks, showed even higher resistance rates in the UKHSA data. Different species can circulate simultaneously, which complicates both surveillance and treatment choices.
Researchers at the University of Cambridge reported in July 2026 that multiple resistant variants are emerging independently rather than from a single strain. Their genomic analysis points to what they call bystander resistance, in which heavy antibiotic use within sexual networks creates conditions favouring resistant strains. Estimates from that study suggest resistant sexually transmitted strains spread around 71 percent faster than susceptible ones. These findings describe patterns in the studied populations and are not predictions for any individual.
Canada recorded an outbreak of 56 cases in Montreal in 2022, mostly among sexually active men, which mirrors the pattern seen elsewhere. UCLA has reported roughly one extensively drug-resistant case per month, compared with one for the whole of 2022. Different countries collect and publish data on different schedules and definitions, so totals are not directly comparable across borders. The consistent signal across all of them is rising resistance rather than rising overall case counts.
The groups most affected by sexually transmitted shigellosis are men who have sex with men, children under five in daycare settings, international travellers and people experiencing homelessness. These groups share close-contact environments or limited access to hygiene facilities, which makes fecal–oral transmission more likely. Being in a risk group does not mean infection is inevitable, and many people in these groups never contract it. Risk depends on specific behaviours and circumstances, not on identity alone.
California public health guidance advises avoiding sex for at least two weeks after diarrhea ends, because people can remain infectious after symptoms stop. It also recommends using barriers for oral and anal sex and washing hands, body and sex toys before and after sexual activity. These measures reduce fecal–oral exposure, which is the main transmission route in sexual settings. Handwashing with soap remains the simplest and most effective general precaution.
Most Shigella infections resolve on their own within about a week, and uncomplicated cases are often managed with fluids and rest rather than medication. Antibiotics are reserved for severe illness or for people at higher risk of complications, but their usefulness is shrinking as resistance spreads. For extensively drug-resistant infections, the CDC notes there is no FDA-approved oral option, which may require alternative routes or agents chosen case by case. Anyone with persistent or bloody diarrhea should seek medical advice rather than self-treat.
An outbreak means a genuine rise in cases above the expected level in a population, while a trend is a pattern of attention or slowly shifting data. The October 2026 surge in searches and posts was a trend; the case counts behind it were roughly stable. The underlying shift, however, is real and gradual: resistant strains are becoming a larger share of infections year by year. Confusing these two ideas is what made the topic feel more dramatic than the numbers supported.
The phrase sexually transmitted diarrhea disease is memorable because it combines two topics people rarely discuss together. Sexually transmitted infections carry stigma, and diarrhea is an uncomfortable subject, so the combination travels quickly online. The framing also implies novelty, even though Shigella has been documented in sexual networks for decades. Viral framing tends to compress a slow, technical story about resistance into a single alarming headline.
Across USA Today, CDC, UKHSA, the University of Cambridge, Healio and ScienceAlert, the same core points appear. Sexually transmitted Shigella is rising in specific populations, resistance to first-line antibiotics is increasing, and there is no sign of an explosive 2026 outbreak. The sources differ in geography and time period: the CDC data cover the United States to 2023, and the UKHSA data cover England to 2025. Where dates differ, the figures should be read as snapshots of those specific periods and places.
The most recent UKHSA figures available are for 2025, with a newer outbreak report extending to March 2026, and no later data have been published. The CDC resistance analysis covers isolates from 2011 to 2023, so it does not describe the current year. Surveillance also depends on people seeking testing, which means reported cases likely undercount actual infections. These gaps mean any statement about the present state of transmission is an estimate rather than a precise measurement.
Sexually transmitted diarrhea is a viral description of a real and slowly worsening problem with antibiotic-resistant Shigella. There was no sudden 2026 outbreak; reported case numbers in the United States were roughly flat compared with 2025. The genuine concern is that extensively drug-resistant strains now make up a measurable share of infections and leave doctors with few oral treatment options. Prevention through hygiene and barrier use during sex remains the most practical step individuals can take.
